{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:32:47Z","timestamp":1791275567342,"version":"4.1.0"},"reference-count":5,"publisher":"American Medical Association (AMA)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,12,19]]},"DOI":"10.1001\/jama.2023.21109","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T11:01:18Z","timestamp":1702983678000},"page":"2304","source":"Crossref","is-referenced-by-count":31,"title":["Use of Donanemab in Early Symptomatic Alzheimer Disease\u2014Reply"],"prefix":"10.1001","volume":"330","author":[{"given":"Cynthia D.","family":"Evans","sequence":"first","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Sims","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"jlr230091r1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","article-title":"Amyloid-related imaging abnormalities and \u00df-amyloid-targeting antibodies: a systematic review.","volume":"79","author":"Filippi","year":"2022","journal-title":"JAMA Neurol"},{"issue":"7806","key":"jlr230091r2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","article-title":"APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline.","volume":"581","author":"Montagne","year":"2020","journal-title":"Nature"},{"issue":"2","key":"jlr230091r3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/ana.v38:2","article-title":"Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy.","volume":"38","author":"Greenberg","year":"1995","journal-title":"Ann Neurol"},{"issue":"6","key":"jlr230091r4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"jlr230091r5","doi-asserted-by":"publisher","first-page":"414","DOI":"10.14283\/jpad.2021.56","article-title":"Donanemab (LY3002813) phase 1b study in Alzheimer\u2019s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging.","volume":"8","author":"Lowe","year":"2021","journal-title":"J Prev Alzheimers Dis"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2812912\/jama_evans_2023_lr_230091_1702929676.70406.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T11:01:21Z","timestamp":1702983681000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2812912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":5,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023,12,19]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.21109","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,19]]}}}